|Bid||103.00 x 800|
|Ask||120.00 x 900|
|Day's Range||115.53 - 118.14|
|52 Week Range||100.57 - 152.55|
|PE Ratio (TTM)||12.51|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.27|
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between United Therapeutics Corporation (NASDAQ:UTHR)’s returnRead More...
From cofounding Sirius Satellite Radio to launching a biotech company to find a cure for her daughter’s illness, Martine Rothblatt has had so much career success that any one of her accomplishments would be a crowning achievement for another entrepreneur. “I always try to convert a moonshot into an earthshot,” Rothblatt told hundreds at the Forbes Women’s Summit on Tuesday. As the CEO of United Therapeutics, which now sells five FDA-approved pills for pulmonary arterial hypertension, Rothblatt is constantly innovating.
SILVER SPRING, Md. and ENGLEWOOD, Colo., June 12, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (XVIVO.ST), today announced that the use of XVIVO's ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics' public benefit corporation subsidiary Lung Biotechnology PBC. "I am excited about trying to make more life-saving use of donated lungs via XVIVO Perfusion's pioneering technology," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "United Therapeutics' impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages," said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).
United Therapeutics Corporation (NASDAQ:UTHR) is currently trading at a trailing P/E of 9.8x, which is lower than the industry average of 26.5x. While this makes UTHR appear like a greatRead More...
Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations. The company, formally called H. Lundbeck A/S, said it had reached an agreement with the U.S. Justice Department, which has investigating drugmakers' support of charities that help Medicare patients cover out-of-pocket drug costs. Lundbeck, which develops and distributes drugs for neurological and psychological diseases such as depression and Alzheimer's, said the settlement would include no admission of wrongdoing and is subject to further negotiation.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
During the first quarter and to date, Correvio announced a strategic transaction with Cipher (CPH.TO) and subsequently closed it, changing their name and ticker symbol in the process. Importantly, as part of the transaction with Cipher, Correvio has received about US$20 million, which should provide sufficient capital to achieve operationally breakeven levels. Sales, general and administrative expenses were $10.9 million, increasing 33% as the company increased the size of its European direct sales force and the recognition of business development and transaction costs related to the Cipher transaction.
Merck & Company’s (MRK) Zetia (ezetimibe) reported revenue of $305 million in Q1 2018 compared to $334 million in Q1 2017, a ~9% fall YoY (year-over-year) and a ~6% fall sequentially.
The Department of Commerce spent $50,000 on the Preakness, consistent with previous years.
SAN RAMON, Calif., May 15, 2018-- SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The Silver Spring biotech is seeing patents expire on some of its key drugs, a longstanding problem. But two analysts say it may not be as bad as it appears.
Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs. The drugmaker said in a filing with the U.S. Securities and Exchange Commission that it reached an agreement in principle with the U.S. Justice Department to pay the sum as part of a civil settlement. Jazz, which produces the expensive narcolepsy drug Xyrem, said in the filing it could not guarantee its efforts to reach a final settlement would be successful.
The final price, a bit more than a billion dollars, includes upfront cash and payments based on achieving certain milestones.
Jerash Holdings (US) and United Therapeutics are stocks on my list that are potentially undervalued. This means their current share prices are trading well-below what the companies are actually worth.Read More...
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
NEW YORK, May 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Reliance ...
In 1Q18, United Therapeutics’ (UTHR) Remodulin generated revenues of $127 million compared to $145.8 million in 1Q17. That was a 13% decline YoY (year-over-year) and a 30% decline quarter-over-quarter.
You might have wondered which CEOs bring home the most pay relative to their employees. This year, you get to find out, courtesy of the Dodd-Frank Act.
LONDON, UK / ACCESSWIRE / May 02, 2018 / Active-Investors.com has just released a free research report on United Therapeutics Corp. (NASDAQ: UTHR). On April 30, 2018, United Therapeutics and SteadyMed Ltd (NASDAQ: STDY) announced the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
The Silver Spring, Maryland-based company said it had profit of $5.57 per share. Earnings, adjusted for stock option gains, came to $3.76 per share. The results missed Wall Street expectations. The average ...